SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Other Events
Item 8.01 Other Events
On December 22, 2016, Second Sight Medical Products, Inc. (the
Company or Second Sight) issued a press release announcing that
following a positive recommendation from advisors to the UK
Governments healthcare funding authority for specialized services
in England, the publicly-funded National Health System (NHS) will
fund blind patients with RP to receive treatment with the Argus
II Retinal Prosthesis System (Argus II) bionic eye.
NHS England has announced that a selective group of severely
blind patients with Retinitis Pigmentosa can have access to Argus
II, the worlds first and only routinely used treatment for severe
blindness. Two implantation centers are being established: the
Manchester Royal Eye Hospital in the north of England, and in the
south, Londons Moorfields Eye Hospital. The hospitals and Second
Sight will also provide follow up, rehabilitation and support to
patients receiving an Argus II implant.
Argus II will be funded via the Commissioning through Evaluation
(CtE) program. The CtE program is especially designed for
treatments that show significant promise for the future, while
new clinical and patient experience data are collected within a
formal evaluation program.
Argus II is already reimbursed under a similar coverage with
evidence development program in France called Forfait Innovation
where patients have benefitted from the Argus II treatment.
A copy of our press release entitled UK Government Announces
Funding for Second Sights Argus II Bionic Eye issued December 22,
2016 is attached as Exhibit 99.1 to this Current Report on Form
8-K, and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description |
| 99.1 | Press Release issued December 22, 2016 |
About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina. SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Recent Trading Information
SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) closed its last trading session 00.00 at 2.24 with 467,645 shares trading hands.
